EANM guidelines on the use of [ 18 F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.

Autor: Nanni C; Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Deroose CM; Nuclear Medicine, University Hospitals (UZ) Leuven, 3000, Leuven, Belgium.; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium., Balogova S; Nuclear Medicine, Comenius University, Bratislava, Slovakia.; Médecine Nucléaire, Hôpital Tenon, GH AP.SU, Paris, France., Lapa C; Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany., Withofs N; Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liege, Liege, Belgium.; GIGA-CRC in Vivo Imaging, University of Liege, Liege, Belgium., Subesinghe M; Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK., Jamet B; Médecine Nucléaire, CHU Nantes, F-44000, Nantes, France., Zamagni E; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy. e.zamagni@unibo.it.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. e.zamagni@unibo.it., Ippolito D; Department of Diagnostic Radiology, Fondazione IRCCS San Gerardo dei Tintori, Via Pergolesi 33, 20900, Monza, Italy.; University of Milano-Bicocca, School of Medicine, Via Cadore 33, 20090, Monza, Italy., Delforge M; University Hospitals (UZ) Leuven, 3000, Leuven, Belgium., Kraeber-Bodéré F; Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, F-44000, Nantes, France.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Dec; Vol. 52 (1), pp. 171-192. Date of Electronic Publication: 2024 Aug 29.
DOI: 10.1007/s00259-024-06858-9
Abstrakt: We provide updated guidance and standards for the indication, acquisition, and interpretation of [ 18 F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [ 18 F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [ 18 F]FDG PET/CT imaging in routine practice and future research.
Competing Interests: Declarations. Human ethics and consent to participate: Not applicable. Competing interests: CN has received consultant honoraria from Keosys and funding from Radius, Immedica, Thema Sinergie. CMD has received consultant honoraria from Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO and Immedica Pharma; his institution has received travel support from GE Healthcare, Sirtex. CL has received research funding from RayzeBio and consultant honoraria from Blue Earth Diagnostics Ltd. (BED, Oxford, UK) and Novartis. NW has received consultant honoraria from Novartis and SCK CEN. EZ has served consulting/advisory role and received honoraria from Janssen, Bristol-Myers Squibb, Sanofi, Amgen, GlaxoSmithKline, Pfizer, Oncopeptides, Menarini Stemline. MD has received speaker honoraria from BMS, GSK, Janssen, Sanofi, Stemline. FKB has received consultant honoraria from Novartis AAA, Telix pharmaceuticals and Immedica and research funding from Siemens. SB, MS, BJ, DI have no relevant financial or non-financial interests to disclose. Liability statement: This guideline summarizes the views of the EANM Oncology and Theranostics Committee. It reflects recommendations for which the EANM cannot be held responsible. The recommendations should be taken into context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: